Clinical trial · Interventional
Clinical and Basic Research on the Treatment of Polycystic Ovary Syndrome
Clinical and Basic Research on the Treatment of Polycystic Ovary Syndrome With Zishen Qingre Lishi Huayu Method: a Multi-center, Double-blind, Randomized and Placebo-controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic ovary syndrome is the most common endocrine and metabolic disorder in gynecology. Traditional Chinese medicine has a good clinical effect in the treatment of PCOS. We intend to conduct this trial in strict accordance with the requirements of evidence-based medicine, through a multi-center, randomized, controlled study, using a double-blind, randomized, placebo-controlled study design method to clarify that Zishen Qingre Lishi Huayu Recipe restores spontaneous ovulation in PCOS patients. The overall efficacy of improving the characteristics of Kaohsiung and glucose and lipid metabolism is optimal, and high-level evidence-based evidence is obtained to form a diagnosis and treatment plan for promotion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Drug | — | UNRESOLVED |
| Zishen Qingre Lishi Huayu Granules | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Therapy group
- interventionNames
- Drug: Zishen Qingre Lishi Huayu Granules
- type
- PLACEBO_COMPARATOR
- label
- Control group
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Ovulation rate
- timeFrame
- The 3-month treatment
- description
- Ovulation rate of each group during the study period Ovulation rate per group = actual total ovulation frequency / total number of cycles (total number of cycles = number of samples).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosed as PCOS patients, the diagnostic criteria are the Rotterdam criteria. All subjects must have: no ovulation, combined with polycystic ovarian or / and hyperandrogenism. 2. Age: 20 to 40 years old, no maternity requirements. 3. Willing to be treated according to the treatment plan specified in this study. Exclusion Criteria: 1. Hyperprolactinemia: In the past year, patients with normal levels can be included. 2. Menopausal FSH levels：FSH \> 15 mIU/mL. In the past year, patients with normal levels can be included. 3. Patients with thyroid disease: TSH \< 0.2 mIU/mL or \>5.5 mIU/mL. In the past year, patients with normal levels can be included. 4. Patients with poorly controlled type 2 diabetes:HbA1c\>7.0%, or patients receiving antidiabetic drugs. 5. Patients currently diagnosed with severe anemia (HGB \<10 g/dL). 6. Patients with a history of alcohol abuse: Alcohol is defined as drinking 14 times a week or more or binge drinking. 7. Currently suspected Cushing's syndrome patients. 8. Patients suspected of having adrenal or ovarian tumors secreting androgen. 9. In patients with hypertension who are currently untreated or have poor blood pressure control, the interval between two blood pressure measurements is ≥ 60 min, systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg. 10. Patients currently diagnosed with metabolic syndrome 11. Take hormonal drugs, Chinese medicine prescriptions and proprietary Chinese medicines in the last 3 months. 12. There is a history of pregnancy in the last 6 weeks. 13. Abortion or production history in the last 6 weeks. 14. A history of breastfeeding in the last 6 months. 15. Patients with a history of deep vein thrombosis, pulmonary embolism or cerebrovascular disease. 16. Patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system, and mental patients 17. Patients who are expected to discontinue treatment during the trial or who are unable to adhere to treatment for 3 months should be excluded. 18. Reluctant to sign the informed consent form for this study.
References
Publications (0)
Data not yet available